Compare
MannKind Corp vs Arcutis Biotherapeutics, Inc. vs Sinovac Biotech Ltd vs Ardelyx, Inc.
| Latest fiscal year | MannKind Corp MNKD | Arcutis Biotherapeutics, Inc. ARQT | Sinovac Biotech Ltd SVA | Ardelyx, Inc. ARDX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $348.97M | $372.07M | $386.01M | $407.32M |
| Revenue growth (YoY) | +22.2% | +123.4% | +6.8% | +22.1% |
| Gross margin | 92.3% (computed) | 90.1% (computed) | 67.9% | 90.3% (computed) |
| Operating margin | 11.1% | -3.3% | -127.0% | -10.1% |
| Net margin | 1.7% | -4.3% | -51.5% | -15.1% |
| Net income | $5.86M | -$16.14M | -$198.84M | -$61.60M |
| EPS (Diluted) | $0.02 | -$0.13 | -$0.83 | -$0.26 |
| Operating cash flow | $18.25M | -$5.62M | -$512.18M | -$42.48M |
| Free cash flow | $13.69M | -$6.31M | -$561.10M | -$43.98M |
| Cash & equivalents | $74.88M | $42.91M | $488.25M | $68.00M |
| Total assets | $792.18M | $432.97M | $8.54B | $501.60M |
| Total liabilities | $843.20M | $243.49M | $2.15B | $334.65M |
| Shareholders' equity | -$51.02M | $189.48M | $6.40B | $166.95M |
| Return on year-end equity | n/a | -8.5% | -3.1% | -36.9% |
| Shares outstanding | 307.83M | 123.33M | 71.86M | 244.35M |
Revenue, most recent five fiscal years
| Fiscal year | MannKind Corp | Arcutis Biotherapeutics, Inc. | Sinovac Biotech Ltd | Ardelyx, Inc. |
|---|---|---|---|---|
| Latest | $348.97M Ended 2025-12-31 | $372.07M Ended 2025-12-31 | $386.01M Ended 2025-12-31 | $407.32M Ended 2025-12-31 |
| 1 year earlier | $285.50M Ended 2024-12-31 | $166.54M Ended 2024-12-31 | $361.37M Ended 2024-12-31 | $333.62M Ended 2024-12-31 |
| 2 years earlier | $198.96M Ended 2023-12-31 | $59.61M Ended 2023-12-31 | $470.17M Ended 2023-12-31 | $124.46M Ended 2023-12-31 |
| 3 years earlier | $99.77M Ended 2022-12-31 | $3.69M Ended 2022-12-31 | $1.47B Ended 2022-12-31 | $52.16M Ended 2022-12-31 |
| 4 years earlier | $75.44M Ended 2021-12-31 | $0 Ended 2021-12-31 | $19.37B Ended 2021-12-31 | $10.10M Ended 2021-12-31 |